Study of Enhanced Programming Stimulation with the Enterra® Therapy System

Inclusion Criteria:

1. Completed informed consent process with signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for theduration of the study

3. Male or female, aged ≥18 or ≤70 years at time of Enterra® therapy implantation

4. Diagnosed with idiopathic or diabetic gastroparesis

5. Delayed solid-phase gastric emptying study (Eggbeaters™ test meal), completed withinone year of patient enrollment in the study. Gastroparesis defined as > 60% retainedat 2 hours and/or >10% retained at 4 hours

6. Investigator confirms normal endoscopy within one year of enrollment in the study

7. GCSI-DD score for nausea severity during the qualifying Baseline Period averaging 2.5 or more per week and vomiting averaging 5 or more episodes per week

Exclusion Criteria:

1. Post-surgical gastroparesis (e.g., fundoplication, Billroth I or II) or other activestomach or gastrointestinal diseases disorders which could explain symptoms in theopinion of the investigator

2. History of pyloroplasty or pyloromyotomy or G-POEM

3. Pregnancy or breastfeeding at the time of consent, or intent to become pregnantduring the study

4. Active H. pylori infection

5. Significant hepatic injury (elevated ALT, AST, bilirubin)

6. Metabolic, mechanical, or mucosal inflammatory causes that may explain GI symptomssuch as gallbladder disease, small bowel bacterial overgrowth, IBS, inflammatorybowel disease, celiac disease, liver or pancreatic disease, or bowel obstruction

7. Patients with significant cardiac or cardiovascular disease, malignancy, or otherconditions

8. Participation in other clinical studies

9. Use of narcotics more than three days per week or other drugs that may affectmotility (e.g., Glucagon-like peptide 1 (GLP-1) agonist drug)

10. Cannabis and/or cannabinoid use that exceeds either:

11. Greater than 3 days of usage per week with 2 or less occurrences each day ofuse, or

12. Greater than 3 grams of total usage per week

13. Previous diagnosis or history of orthostatic intolerance, e.g., POTS,neurocardiogenic syncope, orthostatic hypotension

14. Subject experiences discomfort during stimulation assessment that cannot betolerated

15. Subjects with an underlying disease leading to follow-up by MRI outside of currentMR conditional indications

16. Evidence of a failed response to temporary gastric electrical stimulation